Status:
COMPLETED
Comparison Study of Doxorubicin Versus Epirubicin-induced Cardiotoxicity in Patients With DLBCL
Lead Sponsor:
Fudan University
Conditions:
Lymphoma
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
The aim of this study is to compare CHOP versus CEOP-induced cardiotoxicity in patients with aggressive B-cell lymphoma. The hypothesis is epirubicin is associated with less cardiotoxicity without com...
Detailed Description
The doxorucin-containing regimen (CHOP) and epirubicin-containing regimen (CEOP) are both frequently used in patients with aggress B-cell lymphoma in out institution. According to a Cochrane meta-anal...
Eligibility Criteria
Inclusion
- Previously untreated aggressive B-cell lymphoma
- Age range 18-75 years old
- ECOG performance status 0-2
- Life expectancy of more than 3 months
- Adequate organ function
Exclusion
- Previous serious cardiac disease
- History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix
- Pregnant or lactating women
- Serious uncontrolled diseases and intercurrent infection
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2013
Estimated Enrollment :
398 Patients enrolled
Trial Details
Trial ID
NCT00854568
Start Date
March 1 2009
End Date
February 1 2013
Last Update
August 20 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fudan University Cancer Hospital
Shanghai, Shanghai Municipality, China, 200032